Pandemic influenza vaccine: Characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

BMC Biotechnology

Volumn 12, Issue , 2012, Pages

  Feshchenko, Elena ^a   Rhodes, David G ^a   Felberbaum, Rachael ^a   McPherson, Clifton ^a   Rininger, Joseph A ^a   Post, Penny ^a   Cox, Manon M J ^a  

^a Protein Sciences Corp   (United States)

Author keywords

A(H1N1)pdm09; Baculovirus expression vector system (BEVS); Flublok; H1N1; Influenza pandemic vaccine; Recombinant hemagglutinin

Indexed keywords

A(H1N1)PDM09; BACULOVIRUS EXPRESSION VECTOR SYSTEMS; FLUBLOK; H1N1; INFLUENZA PANDEMICS; RECOMBINANT HEMAGGLUTININ;

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; MANUFACTURE; VACCINES; VIRUSES;

RECOMBINANT PROTEINS;

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PARAINFLUENZA VACCINE; RECOMBINANT PROTEIN; TRIPLE VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PARAINFLUENZA VIRUS; PARTICLE SIZE; PROTEIN DEGRADATION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; SEASONAL INFLUENZA; VIRUS HEMAGGLUTINATION;

AMINO ACID SEQUENCE; ANTIGENS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LIGHT; MOLECULAR SEQUENCE DATA; PANDEMICS; PROTEIN STABILITY; RECOMBINANT PROTEINS; SCATTERING, RADIATION; SEQUENCE ALIGNMENT;

MUS; ORTHOMYXOVIRIDAE;

EID: 84867898126     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-12-77     Document Type: Article

References (25)

1. Monto AS, Black S, Plotkin SA, Orenstein WA. Response to the 2009 pandemic: effect on influenza control in wealthy and poor countries. Vaccine 2011, 29(38):6427-6431. 10.1016/j.vaccine.2011.06.113, 21763381.
2. LaRussa P. Pandemic novel 2009 H1N1 influenza: what have we learned?. Semin Respir Crit Care Med 2011, 32(4):393-399. 10.1055/s-0031-1283279, 21858744.
3. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201. 10.1126/science.1176225, 3250984, 19465683.
4. President's Council of Advisors on Science and Technology Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza 2010, Washington, DC: Executive Office of the President, http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf, .
5. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009, 333:43-82. 10.1007/978-3-540-92165-3_3, 19768400.
6. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009, 8(4):383-389. 10.1586/erv.09.9, 19348555.
7. Robertson JS, Nicolson C, Harvey R, et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011, 29(9):1836-1843. 10.1016/j.vaccine.2010.12.044, 21199698.
8. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (Flublok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29(44):7733-7739. 10.1016/j.vaccine.2011.07.128, 21835220.
9. Cox MM, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011, 107(Suppl):S31-S41.
10. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011, 29(12):2272-2278. 10.1016/j.vaccine.2011.01.039, 21277410.
11. Cox MM, Patriarca PA, Treanor J. Flublok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses 2008, 2(6):211-219. 10.1111/j.1750-2659.2008.00053.x, 19453397.
12. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(13-14):1732-1737.
13. Farnsworth A, Cyr TD, Li C, Wang J, Li X. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 2011, 29(8):1529-1533. 10.1016/j.vaccine.2010.12.120, 21211583.
14. Wei CJ, Boyington JC, Dai K, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010, 2(24):24ra21. 10.1126/scitranslmed.3000799, 3182573, 20375007.
15. Xie H, Doneanu C, Chen W, Rininger J, Mazzeo JR. Characterization of a recombinant influenza vaccine candidate using complementary LC-MS methods. Curr Pharm Biotechnol 2011, 12(10):1568-1579. 10.2174/138920111798357447, 21542793.
16. Skehel JJ, Waterfield MD. Studies on the primary structure of the influenza virus hemagglutinin. Proc Natl Acad Sci U S A 1975, 72(1):93-97. 10.1073/pnas.72.1.93, 432247, 1054518.
17. Williams MS. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 1993, 37:253-262. 10.1016/0378-1135(93)90027-5, 8116186.
18. Khurana S, Verma S, Verma N, et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One 2010, 5(7):e11548. 10.1371/journal.pone.0011548, 2902520, 20634959.
19. Caillet C, Piras F, Bernard MC, et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 2010, 28(18):3076-3079. 10.1016/j.vaccine.2010.02.050, 20193791.
20. Kistner O, Crowe BA, Wodal W, et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5(2):e9349. 10.1371/journal.pone.0009349, 2826398, 20186321.
21. Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing AdvaxTM polysaccharide adjuvant. Vaccine 2012, 30:5407-16. Epub 2012 Jun 17, 10.1016/j.vaccine.2012.06.009, 22717330.
22. Holtz KM, Anderson DK, Cox MM. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J 2003, 2:65-73.
23. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24(12):2176-2185. 10.1016/j.vaccine.2005.11.005, 16310896.
24. Williams MS, Mayner RE, Daniel NJ, et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980, 8(4):289-296. 10.1016/S0092-1157(80)80006-0, 6782106.
25. Kendal AP, Pereira MS, Skehel JJ. Hemagglutination Inhibition. Concepts and procedures for laboratory-based influenza surveillance 1982, B17-B35-19. US Department of Health and Human Services and Pan-American Health Health Organization, Atlanta, GA.